Search
Selected Filter
Displaying 161–170 of 521 news results
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Research NewsThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
Research NewsThe drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
-
Aldeyra Launches Phase 2 Clinical Trial of Methotrexate Intravitreal Injections for RP
Research NewsLab studies showed the drug can effectively address the misfolded rhodopsin protein
-
Foundation News
Trial recruitment is enabled by the Foundation Fighting Blindness’ patient registry, My Retina Tracker® Registry, which includes genetic and vision information for more than 20,000 people with inherited retinal diseases.
-
Neurogene to Launch Gene Therapy Clinical Trial for Children with Batten Disease
Research NewsThe treatment will be delivered to the vitreous of the eye and ventricles of the brain
-
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
In the PressIndustry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Research NewsCompany has been unable to meet revenue goals for the Argus II®
-
Foundation News
The March 6th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
